Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Neoadjuvant for Cisplatin-ineligible High Risk UTUC
NCT04672330Phase 2Completed
- Sponsor
- Renji Hospital
- Start
- Dec 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in upper tract urothelial carcinoma (UTUC), sponsored by Renji Hospital. Started Dec 2020; status: completed.
02
Drugs
tislelizumab
03
Conditions
upper tract urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on NCT04672330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04672330.